A single and multiple ascending dose study to investigate safety, tolerability, pharmacokinetics, and pharmacodynamics of AZD2389 in healthy participants

Study identifier:D7930C00001

ClinicalTrials.gov identifier:NCT06138795

EudraCT identifier:N/A

CTIS identifier:N/A

Recruiting

Official Title

A Phase I, Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD2389 After Single and Multiple Ascending Doses to Healthy Participants.

Medical condition

Healthy Participants

Phase

Phase 1

Healthy volunteers

Yes

Study drug

AZD2389, Placebo

Sex

All

Estimated Enrollment

110

Study type

Interventional

Age

18 Years - 55 Years

Date

Study Start Date: 20 Nov 2023
Estimated Primary Completion Date: 04 Nov 2024
Estimated Study Completion Date: 04 Nov 2024

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Sequential Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Aug 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria